Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President

Chief Financial Officer

Chief Legal Officer

Chief Executive Officer

Chief Commercial Officer

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-24	Premium	sold	Premium	Premium	Premium	-
2024-04-17	Premium	sold	Premium	Premium	Premium	-
2024-04-15	Premium	sold	Premium	Premium	Premium	President
2024-04-10	Premium	sold	Premium	Premium	Premium	-
2024-04-08	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-05	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-03	Premium	sold	Premium	Premium	Premium	-
2024-03-27	Premium	sold	Premium	Premium	Premium	-
2024-03-20	Premium	sold	Premium	Premium	Premium	-
2024-03-15	Premium	sold	Premium	Premium	Premium	President
2024-03-13	Premium	sold	Premium	Premium	Premium	-
2024-03-08	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-07	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-03-04	Premium	sold	Premium	Premium	Premium	President
2024-03-04	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	President
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-29	Premium	sold	Premium	Premium	Premium	President
2024-02-29	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-28	Premium	acquired	Premium	Premium	Premium	President
2024-02-22	Premium	sold	Premium	Premium	Premium	President
2024-02-16	Premium	sold	Premium	Premium	Premium	President

MRNA - Moderna Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MRNA